Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm nivolumab trial in platinum-recurrent or platinum-refractory metastatic germ cell tumors
2017-003336-37Phase 2Terminated
- Sponsor
- Sentigen Holding
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in germ cell tumor (GCT), sponsored by Sentigen Holding. Primary endpoint: clinical benefit rate. Started Apr 2018; status: terminated.
02
Drugs
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2017-003336-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003336-37.